Insmed (NASDAQ:INSM) Reaches New 12-Month High After Analyst Upgrade

Key Points

• Insmed's stock reached a new 52-week high of $146.91 after Guggenheim raised its price target significantly from $125.00 to $172.00, maintaining a buy rating.
• Multiple analysts have adjusted their price targets for Insmed, with a consensus rating of "Moderate Buy" and a target price of $139.86.
• Insider sales are notable, with COO Roger Adsett selling 25,000 shares and CFO Sara Bonstein selling 58,400 shares, reflecting significant decreases in their ownership stakes.

Insmed, Inc. (NASDAQ:INSM - Get Free Report)'s stock price reached a new 52-week high during trading on Monday after Guggenheim raised their price target on the stock from $125.00 to $172.00. Guggenheim currently has a buy rating on the stock. Insmed traded as high as $146.91 and last traded at $145.86, with a volume of 288114 shares. The stock had previously closed at $145.10.

Several other research firms have also issued reports on INSM. Mizuho raised their price target on shares of Insmed from $130.00 to $165.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $111.00 to $135.00 and gave the company an "overweight" rating in a research note on Wednesday, August 20th. Wells Fargo & Company lifted their price objective on shares of Insmed from $140.00 to $171.00 and gave the company an "overweight" rating in a research note on Wednesday, September 3rd. Truist Financial lifted their price objective on shares of Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Finally, HC Wainwright lifted their price target on shares of Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a research report on Wednesday, June 11th. Sixteen equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $139.86.

Insider Buying and Selling

In related news, COO Roger Adsett sold 25,000 shares of the business's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total value of $3,189,500.00. Following the transaction, the chief operating officer directly owned 105,637 shares of the company's stock, valued at approximately $13,477,168.46. The trade was a 19.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sara Bonstein sold 58,400 shares of the business's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the completion of the sale, the chief financial officer owned 73,505 shares in the company, valued at $7,546,758.35. This represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 535,320 shares of company stock worth $54,581,793 in the last ninety days. Corporate insiders own 3.00% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV purchased a new stake in Insmed in the fourth quarter worth approximately $227,000. Baird Financial Group Inc. purchased a new stake in Insmed in the fourth quarter worth approximately $1,539,000. Cetera Investment Advisers boosted its stake in Insmed by 15.0% in the fourth quarter. Cetera Investment Advisers now owns 10,154 shares of the biopharmaceutical company's stock worth $701,000 after buying an additional 1,321 shares in the last quarter. Deutsche Bank AG boosted its stake in Insmed by 76.6% in the fourth quarter. Deutsche Bank AG now owns 488,966 shares of the biopharmaceutical company's stock worth $33,758,000 after buying an additional 212,024 shares in the last quarter. Finally, Ensign Peak Advisors Inc boosted its stake in shares of Insmed by 9.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 529,049 shares of the biopharmaceutical company's stock valued at $36,526,000 after purchasing an additional 44,928 shares during the period.

Insmed Stock Performance

The stock has a market cap of $30.93 billion, a PE ratio of -25.58 and a beta of 0.96. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The business has a 50 day moving average price of $114.64 and a two-hundred day moving average price of $89.74.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. Insmed's revenue was up 18.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.